A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation
Phase of Trial: Phase III
Latest Information Update: 23 Jun 2017
At a glance
- Drugs Benralizumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 19 Dec 2016 Planned End Date changed from 1 Mar 2018 to 1 May 2018.
- 19 Dec 2016 Planned primary completion date changed from 1 Mar 2018 to 1 May 2018.
- 14 Nov 2016 Planned End Date changed from 1 Apr 2018 to 1 Mar 2018.